Endocrine Abstracts

Adrenocortical carcinoma (ACC) is a rare, heterogeneous malignancy with aggressive behavior and poor prognosis, particularly when metastatic at diagnosis. To date, radical surgery, possibly associated to mitotane adjuvant therapy, is considered the best option for ACC treatment. However, the mean 5-year survival rate diminishes dramatically in metastatic ACC and chemo-resistance often develops. Thus, more specific and effective drugs for ACC treatment are urgently required. Th...

Adrenocortical carcinoma (ACC) is a rare, heterogeneous malignancy with a poor prognosis, particularly when metastatic at diagnosis. To date, radical surgery, possibly associated to mitotane adjuvant therapy, is the only available treatment. However, the mean 5-year survival rate drops under 10% in metastatic ACC and chemo-resistance often develops. Thus, more specific and effective drugs for ACC treatment are urgently required. The antidiabetic drug metformin, used in type 2 ...

Objective: Adrenocortical carcinoma (ACC) is a rare malignancy, whose prognosis is mainly dependent on the stage at diagnosis. The identification of disease-associated markers representing solid biomarkers for early diagnosis and drug monitoring is mandatory to improve survival rate and life quality of patients. CTC are tumor cells originating from primary tumor or metastases. The tumor-induced angiogenesis and invasion allow aggressive tumors to release CTC into blood stream ...

Adrenocortical carcinoma (ACC) is a rare and aggressive tumour with a poor prognosis, characterized by radio/chemotherapy resistance. The lack of an effective medical treatment is due to the poor knowledge of the mechanisms underlying malignant tumour transformation and aggressiveness. In vitro studies on the ACC H295R cell model have demonstrated that RGZ, an antidiabetic drug belonging to the thiazolidinedione ligands of PPARgamma, blocks cell proliferation/migration ...

Adrenocortical cancer (ACC) is a rare aggressive malignancy, with poor prognosis when metastaic at diagnosis. Recent ACC pan-genomics analysis contributed to redefine the risk groups on molecular bases, including tumor micro RNA (miR), which can be detectable not only in the primary lesion but also in the bloodstream.We develop a quantitative real-time assay for the measurement of absolute levels in plasma samples of miR483 and its mature miR483-5p form....

Besides their well-known anti-diabetic effects, the peroxisome proliferator-activated receptor γ (PPARγ) thiazolidinedione ligands (TZD) have been suggested to also display anti-inflammatory properties. The receptor role in mediating such effects is far from being elucidated. Here, we demonstrate that PPARγ is necessary for TZD to interfere with TNFα and IFNγ inflammatory activity in human endothelial cells. Different PPARγ ligands similarly inhib...